Gregory N. Dietsch
Directeur Technique/Scientifique/R&D chez VentiRx Pharmaceuticals, Inc.
Postes actifs de Gregory N. Dietsch
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
VentiRx Pharmaceuticals, Inc.
 VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Directeur Technique/Scientifique/R&D | - | - |
| American Board of Toxicology | Corporate Officer/Principal | - | - |
Historique de carrière de Gregory N. Dietsch
Anciens postes connus de Gregory N. Dietsch
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
ICOS Corp.
 ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Corporate Officer/Principal | - | - |
Formation de Gregory N. Dietsch
| Oregon Health & Science University | Doctorate Degree |
| Washington State University | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Health Technology |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Health Technology |
| American Board of Toxicology |
- Bourse
- Insiders
- Gregory N. Dietsch
- Expérience
